Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Jan 16, 2023 1:31pm
102 Views
Post# 35226039

RE:Forcing Bioasis to Answer

RE:Forcing Bioasis to Answer"My understanding is that when asked the question, GD's response is that "There is no Plan B.""

I don't know what's been said but based on the company's public information it has looked to me like the Midatech deal was 'Plan B'. 'Plan A' was the Cresence deal to transform BTI into a clinical stage company and get on NASDAQ. This was supported by the Neuamedy and J&J announcements. All of this may have been enough in a normal market but we've been in a historically bad market for biotech. The market didn't bite and create financial options. Then BTI didn't make its debt payments...

"In July 2022, Lind Partners provided the Company a three-month repayment holiday under the provisions of the convertible security funding agreement. The parties agreed that the next repayment due would be the payment due at the end of September 2022. As of the date of this filing, the Company has not made the September 2022 payment. The Company is in discussions with Lind to modify the agreement, add additional repayment holidays, and lend the Company additional funds, in return for modified repayment terms. As of the date of this filing the modification to the convertible security funding agreement has not been finalized." MD&A
<< Previous
Bullboard Posts
Next >>